Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
← catalyst calendarNCT06795412 · readout in 474 d
Sponsored by Pyxis Oncology, Inc (industry) · PYXS — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
220estimated
Sites
19
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-15 | actual | When the study began enrolling |
| Primary completion | 2027-12-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-06 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: PYX-201
- Drug: pembrolizumab — also filed as KEYTRUDA®
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants who Experience a Dose-Limiting Toxicity (DLT)
measured Day 1 to Day 21
Number of Participants who Experience an Adverse Event (AE)
measured Up to approximately 2 years
Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Parameters
measured Up to approximately 2 years
Number of Participants who Experience Clinically Significant Changes in Vital Signs
measured Up to approximately 2 years
Number of Participants who Experience Clinically Significant Changes in electrocardiogram (ECG) Parameters
measured Up to approximately 2 years
Permalink · PYXS's whole pipeline · Catalyst calendar · Every registered study · What changed